-
公开(公告)号：US5686407A
公开(公告)日：1997-11-11
申请号：US515663
申请日：1995-08-16
CPC分类号： A61K38/1833 , Y10S514/913
摘要： Methods for controlling IOP with compositions of HGF Receptor Activators are disclosed.
摘要翻译： 公开了用HGF受体激活剂组合物控制IOP的方法。
-
62.发明授权Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids 失效通过用血管抑制类固醇治疗预防和治疗眼新生血管形成
公开(公告)号：US5679666A
公开(公告)日：1997-10-21
申请号：US342524
申请日：1994-11-21
申请人： Abbot F. Clark
发明人： Abbot F. Clark
IPC分类号： A61K31/565 , A61K31/57 , C07J3/00 , C07J5/00 , C07J9/00 , C07J11/00 , C07J41/00 , C07J51/00 , A61K31/33
CPC分类号： A61K31/573 , A61K31/565 , A61K31/57 , C07J11/00 , C07J3/00 , C07J41/0005 , C07J41/0027 , C07J5/0053 , C07J51/00 , C07J9/00 , Y10S514/912
摘要： Methods and formulations for treating ocular neovascularization using angiostatic steroids are disclosed.
摘要翻译： 公开了使用血管抑制类固醇治疗眼新生血管形成的方法和制剂。
-
63.发明授权RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma 有权RNAi介导的卷曲相关蛋白-1抑制治疗青光眼公开(公告)号：US09040494B2
公开(公告)日：2015-05-26
申请号：US13429913
申请日：2012-03-26
IPC分类号： A61K48/00 , C07H21/02 , C07H21/04 , C12N15/113 , A61K38/00
CPC分类号： C12N15/113 , A61K9/0048 , A61K31/7088 , A61K31/713 , A61K38/00 , A61K48/00 , C12N2310/111 , C12N2310/14 , C12N2310/316 , C12N2310/321 , C12N2310/351
摘要： RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
摘要翻译： 提供RNA干扰用于抑制卷曲相关蛋白-1 mRNA表达，特别是用于治疗患有青光眼或有发展青光眼风险的患者。
-
64.发明授权RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma 有权RNAi介导的卷曲相关蛋白-1抑制治疗青光眼公开(公告)号：US08173617B2
公开(公告)日：2012-05-08
申请号：US13084944
申请日：2011-04-12
CPC分类号： C12N15/113 , A61K9/0048 , A61K31/7088 , A61K31/713 , A61K38/00 , A61K48/00 , C12N2310/111 , C12N2310/14 , C12N2310/316 , C12N2310/321 , C12N2310/351
摘要： RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
摘要翻译： 提供RNA干扰用于抑制卷曲相关蛋白-1 mRNA表达，特别是用于治疗患有青光眼或有发展青光眼风险的患者。
-
65.发明授权公开(公告)号：US08168609B2
公开(公告)日：2012-05-01
申请号：US12940375
申请日：2010-11-05
申请人： Jon E. Chatterton , Abbot F. Clark
发明人： Jon E. Chatterton , Abbot F. Clark
CPC分类号： C12N15/1137 , A61K31/7084 , C12N2310/14
摘要： RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.
摘要翻译： 提供了用于抑制Rho激酶mRNA表达以治疗眼部疾病患者的RNA干扰，特别是用于治疗眼内压，眼高压和青光眼。 Rho激酶mRNA靶标包括ROCK1和ROCK2的mRNA。
-
66.发明申请Use of chemical chaperones to treat glaucoma caused by misfolded or misprocessed proteins 审中-公开使用化学伴侣来治疗由错误折叠或错误处理的蛋白质引起的青光眼公开(公告)号：US20120101160A1
公开(公告)日：2012-04-26
申请号：US11302839
申请日：2005-12-14
申请人： Allan Shepard , Nasreen Jacobson , Abbot F. Clark
发明人： Allan Shepard , Nasreen Jacobson , Abbot F. Clark
IPC分类号： A61K31/192 , A61P27/06 , A61K31/131 , A61K31/16 , A61K31/205 , A61K31/10
CPC分类号： A61K31/10 , A61K31/14 , A61K31/16 , A61K31/197 , A61K31/205
摘要： The present invention provides methods for treating glaucoma by administering compounds capable of stabilizing misprocessed or misfolded proteins that are responsible for the condition.
摘要翻译： 本发明提供了通过施用能够稳定负责该病症的错误加工或错误折叠的蛋白质的化合物来治疗青光眼的方法。
-
公开(公告)号：US20110256156A1
公开(公告)日：2011-10-20
申请号：US13112635
申请日：2011-05-20
申请人： Jon E. Chatterton , Abbot F. Clark
发明人： Jon E. Chatterton , Abbot F. Clark
IPC分类号： A61K31/7088 , A61K39/395 , A61K38/14 , C07H21/02 , C07K14/79 , A61P9/00 , C07K2/00 , C07K9/00 , A61P27/02 , A61P27/06 , A61P29/00 , A61K38/40 , C07K16/28
CPC分类号： C12N15/113 , A61K9/0048 , A61K31/7088 , A61K31/713 , A61K47/64 , A61K47/644 , A61K47/6849 , C12N15/87 , C12N2310/14 , C12N2310/141 , C12N2310/3513 , C12N2320/32
摘要： The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.
摘要翻译： 本发明提供可用作用于将干扰RNA分子在体外或体内递送至细胞的递送系统的干扰RNA分子 - 配体缀合物。 缀合物包含可结合转铁蛋白受体（TfR）的配体。 还提供了缀合物的治疗用途。
-
68.发明申请RNAI-MEDIATED INHIBITION OF FRIZZLED RELATED PROTEIN-1 FOR TREATMENT OF GLAUCOMA 有权用于治疗葡萄球菌的相关蛋白-1的RNAi介导的抑制公开(公告)号：US20110190381A1
公开(公告)日：2011-08-04
申请号：US13084944
申请日：2011-04-12
IPC分类号： A61K31/7088 , A61P27/06
CPC分类号： C12N15/113 , A61K9/0048 , A61K31/7088 , A61K31/713 , A61K38/00 , A61K48/00 , C12N2310/111 , C12N2310/14 , C12N2310/316 , C12N2310/321 , C12N2310/351
摘要： RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
摘要翻译： 提供RNA干扰用于抑制卷曲相关蛋白-1 mRNA表达，特别是用于治疗患有青光眼或有发展青光眼风险的患者。
-
69.发明申请RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA 有权用于治疗GLAUCOMA的TNFα信号途径的RNAi相关性抑制公开(公告)号：US20110135579A1
公开(公告)日：2011-06-09
申请号：US13024621
申请日：2011-02-10
IPC分类号： A61K31/713 , A61K9/12 , A61P27/02
CPC分类号： C12N15/1138 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是沉默这种TNFα靶标可用于治疗患有TNFα相关病症的患者或具有发展TNFα相关病症的风险，例如与眼内压升高（IOP）相关的眼部病症，包括青光眼和高眼压症。
-
70.发明申请AGENTS WHICH REGULATE, INHIBIT, OR MODULATE THE ACTIVITY AND/OR EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AS A UNIQUE MEANS TO BOTH LOWER INTRAOCULAR PRESSURE AND TREAT GLAUCOMATOUS RETINOPATHIES/OPTIC NEUROPATHIES 审中-公开代理，禁止或调节连接性组织生长因子（CTGF）的活动和/或表达，作为双重下降的压力和治疗玻璃体积反射/视神经病变的独特手段公开(公告)号：US20110092523A1
公开(公告)日：2011-04-21
申请号：US12970662
申请日：2010-12-16
IPC分类号： A61K31/52 , A61K31/4439 , A61P27/02
CPC分类号： A61K31/4439 , A61K31/202 , A61K31/426 , A61K31/427 , A61K31/519 , A61K31/52
摘要： The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).
摘要翻译： 本发明提供了一种通过施用治疗有效量的至少一种抑制结缔组织生长因子的表达和/或信号转导的非核苷酸或非蛋白质试剂来降低眼内压并向有需要的患者提供神经保护作用的方法 CTGF）。
-
-
-
-
-
-
-
-
-
搜索结果
88 条记录 (耗时 0.025 秒)
